PATENT CLAIM ANALYSIS

Application Number: 15753008
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "406000"]

Abstract:
Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Claim (Index 4):
The compound of  claim 2  and/or a pharmaceutically acceptable salt thereof, wherein L 1  is a heterocycloalkyl chosen from pyrrolidinyl, tetrahydrofuranyl, and piperidinyl, each of which is optionally substituted with at least one group chosen from halo, \u2014SO 2 alkyl, and alkyl, wherein the alkyl is optionally substituted with at least one group chosen from halo, hydroxyl, and alkoxy.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 1.5814
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15352184', '14776280', '14135793', '14710631', '13855246']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8251087942088746
- 35 USC 102 Novelty (BERT): 0.548801875002803
- Combined Prediction Score: 0.7974781022882675
- Mean Citation Score: 402.434838
- Max Citation Score: 408.44528
- Similarity Product: 346.3375646022415

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test